INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nektar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 1 ...